Ozempic Pen Volume for 0.25 mg Weekly Dosing
For a patient receiving 0.25 mg of Ozempic weekly, prescribe one 2 mg/1.5 mL pen per month, which provides approximately 8 weeks of therapy at the 0.25 mg dose.
Pen Specifications and Dosing
The Ozempic pen contains 2 mg of semaglutide in 1.5 mL of solution, delivering either 0.25 mg or 0.5 mg doses depending on the pen formulation 1. The 0.25 mg dose is specifically intended as an initiation dose for the first 4 weeks of treatment and is not effective for long-term glycemic control 1.
Standard Titration Schedule
According to FDA-approved dosing:
- Weeks 1-4: 0.25 mg subcutaneously once weekly 1
- Week 5 onward: Increase to 0.5 mg once weekly 1
- Optional escalation: May increase to 1 mg weekly after at least 4 weeks on 0.5 mg if additional glycemic control is needed 1
This titration approach is consistently recommended across multiple guidelines 2, 3, 4, 5.
Practical Prescribing Considerations
One pen provides sufficient medication for approximately 8 doses of 0.25 mg, meaning a single pen covers the entire 4-week initiation period plus an additional 4 weeks 1. However, since patients should advance to 0.5 mg after 4 weeks, prescribing for "one month" at 0.25 mg is only appropriate during treatment initiation 1.
For ongoing monthly prescriptions: After the initial 4-week period, patients require 0.5 mg weekly (4 doses per month), and the pen formulation changes accordingly 1.
Storage and Handling
- Store unused pens refrigerated at 36°F to 46°F (2°C to 8°C) 1
- Once in use, pens may be kept at room temperature (59°F to 86°F) or refrigerated for up to 56 days 1
- Each pen should be discarded after 56 days regardless of remaining medication 1
Important Clinical Caveats
The 0.25 mg dose is not therapeutically effective for diabetes management—it serves solely as a dose-escalation step to minimize gastrointestinal side effects 3, 6, 1. Patients should not remain on 0.25 mg beyond the initial 4-week titration period 1. Gradual dose titration significantly reduces nausea, vomiting, and diarrhea, which are the most common adverse effects occurring in 17-44% of patients 7, 6.